Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RCZ and CHOP for Dual-expressing DLBCL
NCT05527912Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Feb 2023
- Primary completion
- Sep 2024
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tucidinostat and zanubrutinib in diffuse large B-cell lymphoma (DLBCL), sponsored by Sun Yat-sen University. Primary endpoint: Complete Response Rate at End of Treatment at 12 months. Status: unknown.
02
Drugs
tucidinostatzanubrutinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05527912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05527912.